Supplementary Figure S3 from Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
Year: 2023
Type: supplementary-materials
Abstract: A. Subgroup analyses of percent change in Ki67 from baseline to week 2 were performed on KE population based on progesterone receptor status, tumor size, baseline disease stage, tumor grade, baseline lymph node involvement, and baseline Ki67 (index 20%). B. Ki67 changes at baseline, 2 weeks, and end of treatment. C. Geometric mean percentage suppression of Ki67 from baseline to end of treatment by treatment arm. D. Mean percentage rate of response as determined by complete cell cycle arrest (responder: Ki76<2.7) at end of treatment, by treatment arm. E. Effect of study treatment discontinuation on cell proliferation. F. Tissue expression of Ki67 from representative patients who were on treatment or off treatment for more than 4 days.
Authors: Sara A. Hurvitz, Miguel Martin, Michael F. Press, David Chan, María Fernandez-Abad, Edgar Petru, Regan Rostorfer, Valentina Guarneri, Chiun-Sheng Huang, Susana Barriga, Sameera Wijayawardana, Manisha Brahmachary, Philip J. Ebert, Anwar Hossain, Jiangang Liu, Adam Abel, Amit Aggarwal, Valerie M. Jansen, Dennis J. Slamon
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361935934